Haemonetics Financial Ratios
NYSE: HAEHealthcareMedical DevicesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Haemonetics ratio analysis
Haemonetics earned a net margin of 7.3% in FY 2026, down from 12.3% a year earlier. Gross margin was 59.0% compared with a median of 49.0% over the prior 9 years. Return on equity reached 12.2%, meaning Haemonetics generated 0.12 dollars of profit for every dollar of shareholders' equity.
Debt-to-equity stood at 1.54 versus 1.49 the year before, and the current ratio was 2.95. At the end of FY 2026, HAE traded at 26.4 times earnings; across the 9 fiscal years shown, its year-end P/E ranged from 19.1 to 86.1, with a median of 68.2. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Haemonetics financial ratios (annual)
| Ratio | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | 26.36 | 19.09 | 37.27 | 36.94 | 76.01 | 72.28 | 68.21 | 84.12 | 86.07 | — |
| Price / sales | 1.91 | 2.34 | 3.31 | 3.60 | 3.28 | 6.52 | 5.18 | 4.66 | 4.27 | 2.36 |
| Price / book | 3.20 | 3.87 | 4.51 | 5.14 | 4.35 | 7.76 | 8.72 | 6.75 | 5.13 | 2.83 |
| Gross margin | 59.0% | 55.0% | 52.8% | 52.6% | 50.9% | 45.7% | 49.0% | 43.2% | 45.6% | 42.7% |
| Operating margin | 11.7% | 16.3% | 12.6% | 13.4% | 8.1% | 10.3% | 10.5% | 8.6% | 6.2% | -2.2% |
| Net margin | 7.3% | 12.3% | 9.0% | 9.9% | 4.4% | 9.1% | 7.7% | 5.7% | 5.0% | -3.0% |
| Free cash flow margin | 19.5% | 10.5% | 11.0% | 7.0% | 7.6% | 8.2% | 11.1% | 4.2% | 16.1% | 9.4% |
| Return on equity (ROE) | 12.2% | 20.4% | 12.2% | 14.1% | 5.8% | 10.9% | 13.0% | 8.2% | 6.1% | -3.6% |
| Return on assets (ROA) | 4.1% | 6.8% | 5.4% | 6.0% | 2.3% | 4.4% | 6.0% | 4.3% | 3.7% | -2.1% |
| Debt / equity | 1.54 | 1.49 | 0.84 | 0.94 | 1.03 | 0.97 | 0.65 | 0.52 | 0.34 | 0.43 |
| Current ratio | 2.95 | 1.62 | 2.56 | 3.06 | 1.71 | 2.74 | 2.20 | 2.44 | 1.35 | 2.42 |
| Revenue growth | -2.0% | 4.0% | 12.0% | 17.7% | 14.1% | -11.9% | 2.2% | 7.0% | 2.0% | -2.5% |
| EPS growth | -38.1% | 44.5% | 2.2% | 166.7% | -45.8% | 4.7% | 42.3% | 22.4% | — | — |